The news for
Elevance Health (ELV) presents a comprehensive outlook for the healthcare giant. The company is rebounding from a recent sell-off, with
Guggenheim initiating coverage of ELV citing it as of the top medical stocks in the market. Upcoming
Q1 results triggered a rise in the price target. Despite a slide in
Q4, ELV seems to be undervalued. Q1 earnings are much-anticipated and are expected to be significant. ELV posted Q4 sales in line with estimates. However, investor concerns remain after executive VP & president of commercial health benefits, Charles Kendrick, sold stock. The company showcased it is increasing its dividend to $1.71. Despite having some investors lose 24% over the past year, ELV's stock performs better than its underlying earnings growth over the last five years. Although insiders are selling off stock, ELV continues to show resilience amid
Medicaid challenges. It plans for future prosperity with a planned acquisition of IU health plans.
Elevance Health ELV News Analytics from Thu, 10 Oct 2024 07:00:00 GMT to Fri, 11 Apr 2025 19:54:51 GMT -
Rating 4
- Innovation 6
- Information 7
- Rumor -4
